絞り込み

17064

広告

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF mutation-positive melanoma receiving adjuvant vemurafenib.

著者 Ascierto PA , Lewis KD , Di Giacomo AM , Demidov L , Mandalà M , Bondarenko I , Herbert C , Mackiewicz A , Rutkowski P , Guminski A , Simmons B , Ye C , Hooper G , Wongchenko MJ , Goodman GR , Yan Y , Schadendorf D
Ann Oncol.2020 Jan ; 31(1):153-159.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Medical

Research Materials

We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.
PMID: 31912791 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード